2024-10-09 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products. 

**1. Performance Comparison:**

* **Cumulative Return:** LLY has a cumulative return of 851.72%, significantly outperforming the S&P 500 (VOO) with a return of 133.14%. 
* **Relative Strength:**  LLY's current relative strength, as measured by its cumulative return compared to the S&P 500, sits at 718.58, representing 89.27% of the historical range. This indicates a strong historical outperformance relative to the broader market.

**2. Recent Price Movement:**

* **Closing Price:** $887.16
* **5-day Moving Average:** $886.84
* **20-day Moving Average:** $907.05
* **60-day Moving Average:** $895.35
* **Analysis:**  The stock is currently trading slightly below its 5-day moving average, indicating a potential short-term dip. However, it remains above its longer-term moving averages, suggesting a more positive trend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 33.45 (Below 50, indicating potential oversold conditions)
* **PPO (Percentage Price Oscillator):** -0.46 (Negative value, suggesting potential weakness)
* **Delta_Previous_Relative_Divergence:** -4.01 (Negative, implying recent short-term downward price pressure)
* **Expected_Return:** 6.72% (5-year projected return exceeding S&P 500)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | $11.30B | 
| 2024-04-30 | 2.49 | $8.77B |
| 2023-11-02 | -0.06 | $9.50B |
| 2023-08-08 | 1.96 | $8.31B |
| 2023-05-09 | 1.96 | $8.31B |

* **Analysis:**  The latest reported earnings (2024-08-08) exceeded analysts' estimates, indicating a strong performance. The continued growth in revenue suggests strong demand for Eli Lilly's products. 
* **Note:**  For the most recent earnings report, it is essential to check for any specific analyst insights and expectations compared to actual results. 

**5. News and Recent Issues:**

**Recent Market Outlook for LLY:**

* **FINBOLD:**  Analysis suggests that LLY is currently underperforming the market. However, the stock is positioned for growth in the long term, driven by strong pipeline products and market leadership.
* **Analyst Opinions:**  Several analysts have recently upgraded their ratings on LLY, citing the strong earnings performance and the company's robust drug pipeline. 
* **Performance Highlights:**  LLY has shown strong growth in recent quarters, particularly in its diabetes and oncology segments.  

**6. Overall Analysis:**

LLY is a strong company with a robust financial position and a promising outlook. The company's strong earnings performance and pipeline of new drugs suggest potential for continued growth. 

**Key Findings:**

* **Significant Outperformance:** LLY has historically outperformed the market, evidenced by its high relative strength and cumulative returns.
* **Stable Price Action:**  Despite recent short-term volatility, the stock remains above its longer-term moving averages, suggesting a potential for continued growth.
* **Mixed Technical Indicators:**  RSI and PPO indicate potential oversold conditions, while the Expected_Return suggests a promising long-term outlook. 
* **Strong Earnings and Future Potential:**  The latest earnings results highlight continued growth and potential for further expansion in the future.
* **Positive Analyst Sentiment:**  Several analysts have upgraded their ratings on LLY, suggesting confidence in the company's future prospects. 

**Conclusion:**

LLY's strong fundamentals, earnings performance, and future potential make it an attractive investment opportunity. However, current technical indicators suggest caution in the short term, and investors should monitor market sentiment and company news closely for potential changes. 
